Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045, India

Antibodies Market Outlook (2023 to 2033)

The antibodies market size is estimated to be worth US$ 236.9 Billion in 2023 and is anticipated to increase at a CAGR of 13.4% from 2023 to 2033. By 2033, it is anticipated that the market for antibodies would reach US$ 834.2 Billion. The total market value of the antibodies sector represented as global market absolute dollar growth is US$ 597.3 Billion.

The impressive growth of the market is likely to be attributed to multiple factors. The rise in demand for antibodies for repeatable research is one of the main factors driving the antibodies market expansion. The market for antibodies is expanding as a result of expanded proteomics and genomics research fields as well as increased research and development efforts in the life sciences industry.

The market for antibodies is also affected by the expansion of industry-academia collaborations, stem cell and neurobiology research, and the desire to address global unmet medical needs.

Attributes Details
Antibodies market’ HCAGR (2017 to 2022) 12.4%
Antibodies market’ CAGR (2023 to 2033) 13.4%
Market Size for Antibodies (2023) US$ 236.9 Billion
Market Size for Antibodies (2033) US$ 834.2 Billion
Market Size for Antibodies’ Absolute Dollar Growth US$ 597.3 Billion

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Antibodies Market Outlook In Comparison to 2017 to 2022 Performance

Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various types of neurological diseases. A certain type of antibody called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by the vaccinia virus. Rising cases of viral infection are anticipated to drive the demand for antibodies.

National Stem Cell Foundation (NSCF) has reported that about 4% of the global population is affected by some kind of autoimmune disease. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease, and rheumatoid arthritis. Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in the upcoming years.

In April 2021, Xencor commenced its Phase I clinical trial of its newly engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing the treatment of patients with autoimmune diseases. Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. With the expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Growth Trends Witnessed for Antibodies Market

How do Research and Development Activities Impact Antibodies Sales Outlook?

A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies is driving growth opportunities for the antibodies market.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.

Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries. This is expected to positively influence the sales of antibodies.

In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Considering this, the rising application of antibodies in chronic disease treatment is anticipated to create scope for antibodies market expansion in the near future.

How is Increasing Production of Bio-similar Antibodies driving Demand?

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported US$ 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated US$ 659 Million in 2020.

USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.

One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to drive the market in the upcoming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of Adjacent Antibodies Market

Antibodies Market:

Attributes Antibodies Market
CAGR (2023 to 2033) 13.4%
Market Value (2023) US$ 236.9 Billion
Growth Factor Strong investments in medical research and development are anticipated to fuel antibodies’ prospective growth.
Opportunity Low regulatory requirements make it a desirable option for antibody businesses and increase market potential exceptionally quickly.
Key Trends Growing Healthcare Industry Research Increases Demand for Antibody Production

Antibody Fragments Market:

Attributes Antibody Fragments Market
CAGR (2023 to 2033) 5.9%
Market Value (2023) USD 8.01 Billion
Growth Factor Infectious and chronic diseases are becoming more common.
Opportunity The growing geriatric population in developing economies is anticipated to boost industrial demand in the coming years.
Key Trends Antibody Fragments Preferentially Over Alternatives

Antibody Production Market:

Attributes Antibody Production Market
CAGR (2023 to 2033) 13.5%
Market Value (2023) USD 17.96 Billion
Growth Factor A major factor driving growth is the increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics.
Opportunity A focus on Research and Development is an essential strategy for driving the company's long-term growth.
Key Trends The production of therapeutic antibodies is increasing, which is anticipated to drive market growth during the forecast period.

Antibodies Market Country-wise Analysis

Country USA
CAGR (2023 to 2033) 14.1%
HCAGR (2017 to 2022) 13.6%
Country United Kingdom
CAGR (2023 to 2033) 15.9%
HCAGR (2017 to 2022) 15.0%
Country Germany
CAGR (2023 to 2033) 14.5%
HCAGR (2017 to 2022) 14.2%
Country China
CAGR (2023 to 2033) 13.6%
HCAGR (2017 to 2022) 11.4%
Country India
CAGR (2023 to 2033) 13.6%
HCAGR (2017 to 2022) 12.3%

Why is USA Dominating the Global Antibodies Market?

The USA is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and the presence of leading market players in the country. The increasing purchasing power of consumers, along with increasing government funding, is anticipated to drive the growth opportunities for the antibodies market, along with the emerging markets for the antibodies sector.

Attributes Details
USA Market Size (2033) US$ 368.9 Billion
USA Market Absolute Dollar Growth (US$ Million/Billion) US$ 270.2 Billion

National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in the USA grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country are anticipated to further increase the demand for antibodies.

National Stem Cell Foundation (NSCF) states that autoimmune diseases are the third most common reason for chronic ailments in the USA Increasing cases of diabetes and multiple sclerosis in the country are anticipated to positively influence the demand for antibodies.

Is the United Kingdom Investment-worthy Market?

Attributes Details
United Kingdom Market Size (2033) US$ 42.5 Billion
United Kingdom Market Absolute Dollar Growth (US$ Million/Billion) US$ 32.8 Billion

Due to the increased prevalence of malignancies, cardiovascular illnesses, autoimmune diseases, and high spending on antibody Research and Development, the United Kingdom for antibodies is also anticipated to account for a sizeable portion of global sales of antibodies.

In addition to this, high investments made by the government towards keeping up the health of their citizens are directing the market towards advancement.

Is Germany an Opportune Market for Antibody?

Attributes Details
Germany Market Size (2033) US$ 32.5 Billion
Germany Market Absolute Dollar Growth (US$ Million/Billion) US$ 24.1 Billion

Germany's antibody market has grown as a result of some of the top companies in the nation's sector, whose products are in great demand. The market is anticipated to see a profit from disease prevalence as well as Germany's high treatment spending capacity on cutting-edge medicines.

The market size for antibodies is anticipated to be impacted by ongoing technological developments, more accessibility, and increased disposable income.

How would Antibodies Market Growth Unfold in China?

Attributes Details
China Market Size (2033) US$ 35.6 Billion
China Market Absolute Dollar Growth (US$ Million/Billion) US$ 25.7 Billion

World Bank evaluated that healthcare expenditure in China accounted for 5.35% of its gross domestic product (GDP) in 2018. The rising geriatric population and associated ailments are anticipated to drive market growth for antibodies in the upcoming years.

Development and production of antibodies in China are expected to increase significantly owing to increasing government investment towards drug development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer, and infections. China developed its first USA Food and Drug Administration (FDA) approved antibody in March 2018. The antibody named Trogarzo was useful in treating resistant HIV infections. Similarly, more than ten other China-made biologics are under clinical trials.

The government also started a Chinese Antibody Society with the aim of assisting in speedy FDA approval as well as ensuring effective marketing of China-made antibody-based therapeutics. These initiatives are expected to reflect positively on the China market, presenting a conducive environment for the growth in sales of antibodies.

What is Influencing Antibodies Market Growth in India?

Attributes Details
India Market Size (2033) US$ 30.3 Billion
India Market Absolute Dollar Growth (US$ Million/Billion) US$ 21.9 Billion

Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with the development of the healthcare system in the country.

As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. A surge in cancer patients is anticipated to drive the demand for antibodies for cancer treatment.

Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare are anticipated to create opportunities for antibodies market growth in India.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Analysis for Market Segmentation of Antibodies Sector

Why Are Cancer Antibodies Gaining Popularity?

Top Disease Indication Cancer
HCAGR (2017 to 2022) 13.4%
CAGR (2023 to 2033) 14.8%

The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing non-invasive and safe treatment options. With the focus on cancer research increasing, the antibodies market outlook for the upcoming decade is anticipated to remain positive.

According to disease indications, the cancer sector is the largest shareholder in the antibodies market, owing to increased cancer prevalence and increased adoption of antibodies in cancer treatment. An increase in the number of drug pipelines, an increase in demand for biosimilar monoclonal antibodies, and an increase in patient awareness of cancer treatment methods boost market expansion.

The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With the focus on cancer research increasing, the antibodies market outlook for the upcoming decade is anticipated to remain positive.

Which Product is likely to Register High Demand?

Top Product Type Monoclonal Antibodies
HCAGR (2017 to 2022) 12.4%
CAGR (2023 to 2033) 13.6%

Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category are anticipated to rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in the geriatric population across the globe.

The rising demand for effective treatment of aforementioned chronic ailments is anticipated to remain a chief growth driver in this category for the antibodies market.

Who is the Leading End User of Antibodies?

Hospitals are expected to generate the highest demand throughout the forecast period. A growing pool of patients and faster accessibility to healthcare is anticipated to elevate the demand in Hospitals.

Hospitals around the world register a higher footfall of patients as they offer expert care and the infrastructure required for administering the necessary treatment. The demand for antibodies in hospitals multiplied amid the pandemic. Even as governments roll out vaccination drives to contain the pandemic, hospitals are anticipated to remain the dominant end-user on account of rising cases of various types of chronic ailments.

Startup Ecosystem: How Lucrative is the Antibodies Market for New Businesses?

Startups Should Concentrate on Increasing the Scope of Their Research to Promote Innovation.

Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.

  • Great Bay Bio (GBB), a start-up with headquarters in Hong Kong, declared in September 2022 that it had successfully raised US$ 15 million in its Pre-series B investment round. The financing is to be put to use by the business to quicken the creation of bioprocessing platforms that are powered by artificial intelligence (AI) in order to enhance the CMC process for a variety of biological pharmaceuticals, such as monoclonal antibodies and fusion proteins.
  • Capstan Therapeutics, a startup with the goal of creating treatments for conditions with unmet medical needs, declared its launch in September 2022 and provided US$ 165 million for in-vivo cell engineering. The business is creating in-vivo CAR treatments, which allow for cell engineering while the patient is still receiving treatment.

Reputable market giants are starting new collaborations and projects that may help emerging markets for the antibodies sector succeed in the very competitive antibodies market.

  • Versant Ventures, a well-known investor in biotechnology startups, announced a new relationship with AbCellera, a business specializing in antibody development, in July 2022. Through this collaboration, Versant significantly speed up the research and development process by supplying start-ups with antibodies from AbCellera that are tailored to their target disease.

How Competition Influences the Market?

Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long-acting antibody drugs to reduce healthcare costs.

In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.

Recent Development:

  • Research: Investigational Oral Treatment

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

  • Acquisition: Johnson & Johnson and Momenta Pharmaceuticals Inc.

In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities for the antibodies market through expansion into autoantibody-driven disease.

  • Partnership: Sanofi and IGM Biosciences

Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately US$ 6 billion in possible milestone payments through this agreement.

Key Players for Antibodies Market

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

Key Segments

By Disease Indication:

  • Cardiovascular Diseases
  • CNS Disorders
  • Cancer
  • Autoimmune Disorders

By Product Type:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody-drug Complexes

By End User:

  • Hospitals
  • Long-term Care Facilities
  • Research Institutes

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan
  • Japan
  • Middle East and Africa(MEA)

Frequently Asked Questions

The market is predicted to grow at a CAGR of 13.4% through 2033.

The USA market holds the highest revenue potential.

The market size is anticipated to be US$ 236.9 Billion in 2023.

The market is expected to be around US$ 834.2 Billion by 2033.

Table of Content

1. Executive Summary | Antibodies Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity ;

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033

        5.3.1. Cardiovascular Diseases

        5.3.2. CNS Disorders

        5.3.3. Cancer

        5.3.4. Autoimmune Disorders

    5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        6.3.1. Monoclonal

        6.3.2. Polyclonal

        6.3.3. Antibody-drug Complexes

    6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Long-term Care Facilities

        7.3.3. Research Institutes

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. Asia Pacific Excluding Japan

        8.3.6. Japan

        8.3.7. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Disease Indication

        9.2.3. By Product Type

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Indication

        9.3.3. By Product Type

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Argentina

            10.2.1.2. Brazil

            10.2.1.3. Mexico

            10.2.1.4. Rest of Latin America

        10.2.2. By Disease Indication

        10.2.3. By Product Type

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Indication

        10.3.3. By Product Type

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. United Kingdom

            11.2.1.2. Germany

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Nordic

            11.2.1.7. Benelux

            11.2.1.8. Rest of Western Europe

        11.2.2. By Disease Indication

        11.2.3. By Product Type

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Indication

        11.3.3. By Product Type

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Russia

            12.2.1.2. Poland

            12.2.1.3. Rest of Eastern Europe

        12.2.2. By Disease Indication

        12.2.3. By Product Type

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Indication

        12.3.3. By Product Type

        12.3.4. By End User

    12.4. Key Takeaways

13. APEJ Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. India

            13.2.1.3. ASEAN

            13.2.1.4. Australia & New Zealand

            13.2.1.5. Rest of Asia Pacific Excluding Japan

        13.2.2. By Disease Indication

        13.2.3. By Product Type

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Indication

        13.3.3. By Product Type

        13.3.4. By End User

    13.4. Key Takeaways

14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

        14.2.2. By Disease Indication

        14.2.3. By Product Type

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Indication

        14.3.3. By Product Type

        14.3.4. By End User

    14.4. Key Takeaways

15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. North Africa

            15.2.1.4. Rest of Middle East and Africa(MEA)

        15.2.2. By Disease Indication

        15.2.3. By Product Type

        15.2.4. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Disease Indication

        15.3.3. By Product Type

        15.3.4. By End User

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Disease Indication

            16.1.2.2. By Product Type

            16.1.2.3. By End User

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Disease Indication

            16.2.2.2. By Product Type

            16.2.2.3. By End User

    16.3. Argentina

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Disease Indication

            16.3.2.2. By Product Type

            16.3.2.3. By End User

    16.4. Brazil

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Disease Indication

            16.4.2.2. By Product Type

            16.4.2.3. By End User

    16.5. Mexico

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Disease Indication

            16.5.2.2. By Product Type

            16.5.2.3. By End User

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Disease Indication

            16.6.2.2. By Product Type

            16.6.2.3. By End User

    16.7. Germany

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Disease Indication

            16.7.2.2. By Product Type

            16.7.2.3. By End User&

    16.8. France

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Disease Indication

            16.8.2.2. By Product Type

            16.8.2.3. By End User

    16.9. Spain

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Disease Indication

            16.9.2.2. By Product Type

            16.9.2.3. By End User

    16.10. Italy

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Disease Indication

            16.10.2.2. By Product Type

            16.10.2.3. By End User

    16.11. Nordic

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Disease Indication

            16.11.2.2. By Product Type

            16.11.2.3. By End User

    16.12. Benelux

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Disease Indication

            16.12.2.2. By Product Type

            16.12.2.3. By End User

    16.13. Russia

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Disease Indication

            16.13.2.2. By Product Type

            16.13.2.3. By End User

    16.14. Poland

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Disease Indication

            16.14.2.2. By Product Type

            16.14.2.3. By End User

    16.15. China

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Disease Indication

            16.15.2.2. By Product Type

            16.15.2.3. By End User

    16.16. India

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Disease Indication

            16.16.2.2. By Product Type

            16.16.2.3. By End User

    16.17. ASEAN

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Disease Indication

            16.17.2.2. By Product Type

            16.17.2.3. By End User

    16.18. Australia & New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Disease Indication

            16.18.2.2. By Product Type

            16.18.2.3. By End User

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Disease Indication

            16.19.2.2. By Product Type

            16.19.2.3. By End User

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Disease Indication

            16.20.2.2. By Product Type

            16.20.2.3. By End User

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Disease Indication

            16.21.2.2. By Product Type

            16.21.2.3. By End User

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Disease Indication

        17.3.3. By Product Type

        17.3.4. By End User

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Novartis AG

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. F. Hoffmann-La Roche AG

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Johnson & Johnson

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Takeda Pharmaceutical Company Limited

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Amgen Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Biogen Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Bristol-Myers Squibb Company

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. AbbVie Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Sanofi SA

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Eli Lilly and Co.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 21: APEJ Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 22: APEJ Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 23: APEJ Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 24: APEJ Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 25: Japan Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 26: Japan Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 27: Japan Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 28: Japan Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Product Type, 2017 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by End User, 2017 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 17: Global Market Attractiveness by Disease Indication, 2023 to 2033

Figure 18: Global Market Attractiveness by Product Type, 2023 to 2033

Figure 19: Global Market Attractiveness by End User, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 37: North America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 38: North America Market Attractiveness by Product Type, 2023 to 2033

Figure 39: North America Market Attractiveness by End User, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Product Type, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Disease Indication, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Product Type, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Disease Indication, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Product Type, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: APEJ Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 102: APEJ Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 103: APEJ Market Value (US$ Million) by End User, 2023 to 2033

Figure 104: APEJ Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: APEJ Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 106: APEJ Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: APEJ Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: APEJ Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 109: APEJ Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 110: APEJ Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 111: APEJ Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 112: APEJ Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 113: APEJ Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 114: APEJ Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 115: APEJ Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 116: APEJ Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 117: APEJ Market Attractiveness by Disease Indication, 2023 to 2033

Figure 118: APEJ Market Attractiveness by Product Type, 2023 to 2033

Figure 119: APEJ Market Attractiveness by End User, 2023 to 2033

Figure 120: APEJ Market Attractiveness by Country, 2023 to 2033

Figure 121: Japan Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 122: Japan Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 123: Japan Market Value (US$ Million) by End User, 2023 to 2033

Figure 124: Japan Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Japan Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 126: Japan Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Japan Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Japan Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 129: Japan Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 130: Japan Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 131: Japan Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 132: Japan Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 133: Japan Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 134: Japan Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 135: Japan Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 136: Japan Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 137: Japan Market Attractiveness by Disease Indication, 2023 to 2033

Figure 138: Japan Market Attractiveness by Product Type, 2023 to 2033

Figure 139: Japan Market Attractiveness by End User, 2023 to 2033

Figure 140: Japan Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Product Type, 2017 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 157: MEA Market Attractiveness by Disease Indication, 2023 to 2033

Figure 158: MEA Market Attractiveness by Product Type, 2023 to 2033

Figure 159: MEA Market Attractiveness by End User, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Antibody Therapy Market

Published : February 2023

Healthcare

Antibiotic Susceptibility Testing Market

Published : July 2022

Explore Healthcare Insights

View Reports